POMDOCTOR shareholders approve 10-for-1 reverse split

The approved resolution would reduce authorized shares from 500,000,000 to 50,000,000; the separate ADR termination and direct-listing vote was advisory.

Rhea-AI Filing Summary

POMDOCTOR Limited shareholders approved a 10-to-1 consolidation of issued and unissued share capital. The resolution provides that it will take effect simultaneously with termination of the American Depositary Receipt program and the direct listing of Class A ordinary shares on The Nasdaq Stock Market. It also amends the authorized share count from 500,000,000 shares to 50,000,000 shares.

Shareholders separately approved ADR termination and the direct listing on a non-binding advisory basis. The reported vote totals were 45,387,346 votes for the consolidation and 45,395,656 for the advisory proposal; the totals are calculated by voting power and exclude 7,639,947 discretionary proxies separately reported by the Inspector of Election. The resolution provides that fractional shares will be aggregated and rounded up to the nearest whole share at the participant level.

Key Figures

Share consolidation ratio: 10-to-1 Authorized shares: 500,000,000 shares to 50,000,000 shares Shares outstanding: 27,802,964 ordinary shares +2 more

5 metrics

Share consolidation ratio 10-to-1 Approved consolidation of issued and unissued share capital.

Authorized shares 500,000,000 shares to 50,000,000 shares Authorized share count before and after the approved amendment.

Shares outstanding 27,802,964 ordinary shares At close of business on September 2, 2026.

Votes for consolidation proposal 45,387,346 votes Calculated by voting power; reported results exclude 7,639,947 discretionary proxies separately reported by the Inspector of Election.

Votes for ADR termination and direct listing proposal 45,395,656 votes Non-binding advisory proposal; reported results are calculated by voting power and exclude 7,639,947 discretionary proxies separately reported by the Inspector of Election.

Key Terms

American Depositary Receipt program, direct listing, ordinary resolution, fractional shares, +1 more

5 terms

American Depositary Receipt program financial

"termination of the Company's American Depositary Receipt program"

direct listing financial

"direct listing of the Class A Ordinary Shares"

A direct listing is a way for a company to become publicly available for trading without issuing new shares or raising additional money beforehand. Instead, existing shares are simply made available for purchase on the stock market, allowing current investors and employees to sell their holdings. This process can offer a simpler and faster way for a company to go public, giving investors quicker access to buy and sell shares.

ordinary resolution regulatory

"approved as ordinary resolution"

An ordinary resolution is a decision made by shareholders at a company meeting that is approved when more than half of the votes cast are in favor. Think of it like a household vote where a majority decides routine matters — it covers everyday corporate actions such as approving directors, routine policy changes, or distributions, and matters to investors because these majority-approved choices shape governance, management authority, and the company’s near-term direction.

fractional shares financial

"No fractional shares will be issued in connection with the Share Consolidation"

Fractional shares are portions of a whole share of a stock or fund, allowing investors to own less than one full unit. They make it possible to invest a specific dollar amount rather than buy whole shares, like buying a slice of a pizza instead of the entire pie. For investors this lowers the cost barrier, helps with diversification, and lets you reinvest dividends or purchase expensive stocks in small, precise amounts.

discretionary proxies regulatory

"exclude 7,639,947 discretionary proxies provided to Guoji Luo"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were the POM shareholder vote totals?

The consolidation proposal received 45,387,346 votes for, and the non-binding advisory proposal on ADR termination and direct listing received 45,395,656 votes for. The reported results are calculated by voting power and exclude 7,639,947 discretionary proxies provided to Guoji Luo for Class A shares underlying ADSs; the Inspector of Election reported those separately.

How will fractional shares be treated in POM's consolidation?

No fractional shares will be issued. After aggregating the fractional shares a shareholder would otherwise receive, the result will be rounded up to the nearest whole share at the participant level.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:06 PM Accepted by SEC EDGAR 10/02/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934

For the month of October 2026

Commission File Number 001-42749

POMDOCTOR LIMITED

Yongxu Industrial Park
No. 19-23 Hejing Road, Dongsha Street
Liwan District, Guangzhou
People’s Republic of China 510000

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F            ☐ Form 40-F

Results of Extraordinary General Meeting of Shareholders

On September 30, 2026, POMDOCTOR LIMITED, a Cayman Islands exempted company (the “Company”), held its extraordinary general meeting of shareholders (the “Meeting”) at 9:00 a.m. Eastern Time (9:00 p.m. Beijing Time) at Yongxu Industrial Park, No. 19-23 Hejing Road, Dongsha Street, Liwan District, Guangzhou, People’s Republic of China 510000.

At the close of business on September 2, 2026 (the “Record Date”), 27,802,964 ordinary shares were issued and outstanding, comprising 25,760,922 Class A ordinary shares, par value US$0.0001 per share (the “Class A Ordinary Shares”), and 2,042,042 Class B ordinary shares, par value US$0.0001 per share (the “Class B Ordinary Shares”). Each Class A Ordinary Share was entitled to one vote, and each Class B Ordinary Share was entitled to twenty votes, for an aggregate of 66,601,762 votes.

Shareholders holding 12,229,680 Class A Ordinary Shares and 2,042,042 Class B Ordinary Shares were present in person or represented by proxy at the Meeting, representing an aggregate of 53,070,520 votes. Accordingly, a quorum was present.

The following proposals were presented to the shareholders at the Meeting:

1. Proposal No. 1: Approval, on a non-binding advisory basis, of the termination of the Company’s American Depositary Receipt program, including the termination of the related deposit agreement, as amended (the “ADR Termination”), and the direct listing of the Class A Ordinary Shares on The Nasdaq Stock Market LLC (the “Listing”), with the ADR Termination and the Listing to occur on the same date.

2. Proposal No. 2: Approval, as an ordinary resolution, that the Company’s share capital (whether issued or unissued) be consolidated at a ratio of 10-to-1, such that (i) every ten (10) Class A Ordinary Shares of a par value of US$0.0001 each be consolidated into one Class A Ordinary Share of a par value of US$0.001 each, (ii) every ten (10) Class B Ordinary Shares of a par value of US$0.0001 each be consolidated into one Class B Ordinary Share of a par value of US$0.001 each, and (iii) every ten (10) shares of a par value of US$0.0001 each of such class or classes (however designated) as the Board may determine in accordance with the Memorandum and Articles of Association of the Company be consolidated into one share of such class or classes of a par value of US$0.001 each (the “Share Consolidation”), which shall take effect simultaneously with the ADR Termination and the Listing, and simultaneously with the Share Consolidation, the authorized share capital of the Company be amended:

FROM: US$50,000 divided into 500,000,000 shares comprising (i) 450,000,000 Class A Ordinary Shares of a par value of US$0.0001 each, (ii) 2,042,042 Class B Ordinary Shares of a par value of US$0.0001 each, and (iii) 47,957,958 shares of a par value of US$0.0001 each of such class or classes (however designated) as the Board may determine in accordance with the Memorandum and Articles of Association of the Company.

1

TO: US$50,000 divided into 50,000,000 shares comprising (i) 45,000,000 Class A Ordinary Shares of a par value of US$0.001 each, (ii) 204,205 Class B Ordinary Shares of a par value of US$0.001 each, and (iii) 4,795,795 shares of a par value of US$0.001 each of such class or classes (however designated) as the Board may determine in accordance with the Memorandum and Articles of Association of the Company.

No fractional shares will be issued in connection with the Share Consolidation, and all fractional shares (after aggregating all fractional shares that would otherwise be received by a shareholder) resulting from the Share Consolidation shall instead be rounded up to the nearest whole number of shares on a participant level.

Proposal No. 3 pertaining to the adjournment of the Meeting was not presented to the shareholders at the Meeting given that sufficient votes to approve Proposal No. 1 and Proposal No. 2 had been cast.

Set forth below are the voting results for each of the proposals⁽¹⁾:

PROPOSAL		FOR				AGAINST				ABSTAIN
Proposal No.1 - ADR Termination Proposal			45,395,656				34,398				519
Proposal No.2 - Share Consolidation Proposal			45,387,346				39,999				3,228

Based on the foregoing voting results, Proposal No. 1 received advisory shareholder approval by way of an ordinary resolution, and Proposal No. 2 was approved as ordinary resolution as required under the Memorandum and Articles of Association of the Company.

(1) Certain Class A Ordinary Shares were represented by the Company’s American Depositary Shares and the voting results set forth above are calculated based on voting power. The foregoing voting results exclude 7,639,947 discretionary proxies provided to Guoji Luo in respect of the underlying Class A Ordinary Shares represented by ADSs, which were separately reported by the Inspector of Election.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	POMDOCTOR LIMITED
	By:	/s/ Zhenyang Shi
	Name:	Zhenyang Shi
	Title:	Chairman and Chief Executive Officer

Date: October 2, 2026

3